Cardior Pharmaceuticals said Thursday that it has received CE marking for its CardiorHealth miR-132 PCR kit.
The kit measures circulating microRNA-132 in the blood of patients who have received the company's oligonucleuotide-based miR-132 inhibitor, CDR132L.
Cardior is conducting a Phase 2 clinical study, HF-REVERT, to evaluate the safety and efficacy of CDR132L in patients with heart failure and reduced left ventricular ejection fraction after a myocardial infarction.
By selectively blocking aberrant miR-132 levels, CDR132L has the potential to reverse cellular pathology and restore normal cardiac function, the firm said.
The CardiorHealth miR-132 PCR kit is designed to monitor the treatment with a noncoding RNA-based therapeutic platform, it added.